PBI-Gordon Companies, Inc., an organization that inspires innovations for green spaces, pets, and people, announces the strategic acquisition of TriviumVet®, a leading research and development company advancing innovative treatments for chronic conditions in cats and dogs. The move is the largest transaction in the company’s 77-year history and includes the addition of an innovative new product, Felycin®-CA1, to the PRN® Pharmacal portfolio of products. Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the first U.S Food and Drug Administration (FDA)-conditionally approved drug for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), which affects as many as one in seven cats.
Read the full article: PBI-Gordon Companies Acquires TriviumVet, Expanding Portfolio of Innovative Treatments in Pet Health //
Source: https://www.prnewswire.com/news-releases/pbi-gordon-companies-acquires-triviumvet-expanding-portfolio-of-innovative-treatments-in-pet-health-302445353.html